Literature DB >> 10924868

The impact of epilepsy from the patient's perspective II: views about therapy and health care.

R S Fisher1, B G Vickrey, P Gibson, B Hermann, P Penovich, A Scherer, S G Walker.   

Abstract

A national survey of 1023 people with epilepsy in the US assessed their attitudes about their therapies. Subjects were drawn from responders to a previous national survey of US households or from those who phoned the Epilepsy Foundation. Overall response rate was 49%. Approximately 90% of the respondents were taking medications for their epilepsy. Only 56% were on monotherapy, while 26% were taking two, 6% three, and 2% four medications. Only 68% of respondents were very satisfied with their current seizure medications. When asked to rank five areas of importance regarding their seizure medication, the rank order (highest to lowest) was seizure control, fewer side effects, convenient dosing regimens and cost. Adverse medication events were listed in descending rank order as problems with cognition, energy level, school performance, childbearing, coordination, and sexual function. Inter-individual differences in side effects of concern were listed, suggesting medication choices should be individualized according to potential side effects. Twenty percent of 920 respondents adjusted their medications on their own, by adjusting amount (62%), dosing schedule (31%), or both (3%). Eighty percent of respondents were satisfied with their medical care systems. In this group, 82% had health insurance that covered epilepsy. The large majority (94%) of respondents had seen a neurologist. Subjects expressed dissatisfaction about time limits and lack of accessible information about epilepsy. People with epilepsy are generally satisfied with efforts to treat their disorder, but adverse events are of concern. Many patients requested more information about epilepsy.

Entities:  

Mesh:

Year:  2000        PMID: 10924868     DOI: 10.1016/s0920-1211(00)00128-5

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  10 in total

Review 1.  Cognitive and fatigue side effects of anti-epileptic drugs: an analysis of phase III add-on trials.

Authors:  Rani A Sarkis; Yazel Goksen; Yi Mu; Bernard Rosner; Jong Woo Lee
Journal:  J Neurol       Date:  2018-07-12       Impact factor: 4.849

2.  Self-Esteem, Social Phobia and Depression Status in Patients with Epilepsy.

Authors:  Ayşe Kutlu; Gökçen Gökçe; Ülkü Büyükburgaz; Macit Selekler; Sezer KOMŞUOğLU
Journal:  Noro Psikiyatr Ars       Date:  2013-12-01       Impact factor: 1.339

3.  Health-care access among adults with epilepsy: The U.S. National Health Interview Survey, 2010 and 2013.

Authors:  David J Thurman; Rosemarie Kobau; Yao-Hua Luo; Sandra L Helmers; Matthew M Zack
Journal:  Epilepsy Behav       Date:  2015-11-25       Impact factor: 2.937

Review 4.  [Primary brain tumors and brain metastases. Symptomatic epilepsy and driving ability - systematic review and expert opinion].

Authors:  P S Reif; A Strzelczyk; S Rüegg; A H Jacobs; A Haag; A Hermsen; U Sure; S Knake; H M Hamer; H Strik; G Krämer; R Engenhart-Cabilic; F Rosenow
Journal:  Nervenarzt       Date:  2010-12       Impact factor: 1.214

5.  Factors associated with seizure recurrence in epilepsy patients treated with antiepileptic monotherapy: A retrospective observational cohort study using US administrative insurance claims.

Authors:  Natalia Shcherbakova; Karen Rascati; Carolyn Brown; Kenneth Lawson; Suzanne Novak; Kristin M Richards; Linda Yoder
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 6.  Expanding therapeutic options: devices and the treatment of refractory epilepsy.

Authors:  Steven Karceski; Paul Mullin
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

7.  A protocol for a randomised controlled, double-blind feasibility trial investigating fluoxetine treatment in improving memory and learning impairments in patients with mesial temporal lobe epilepsy: Fluoxetine, Learning and Memory in Epilepsy (FLAME trial).

Authors:  Cheney J G Drew; Mark Postans; Cateno Petralia; Rachel McNamara; Philip Pallmann; Dave Gillespie; Lisa H Evans; Nils Muhlert; Mia Winter; Khalid Hamandi; William P Gray
Journal:  Pilot Feasibility Stud       Date:  2019-07-06

8.  Concerns with AED conversion: comparison of patient and physician perspectives.

Authors:  Brien J Smith; Erik K St Louis; John M Stern; Chad Green; Thomas Bramley
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

9.  Managing patient adherence and quality of life in epilepsy.

Authors:  Joanne Eatock; Gus A Baker
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

10.  Disease Modification by Combinatorial Single Vector Gene Therapy: A Preclinical Translational Study in Epilepsy.

Authors:  Esbjörn Melin; Avtandil Nanobashvili; Una Avdic; Casper R Gøtzsche; My Andersson; David P D Woldbye; Merab Kokaia
Journal:  Mol Ther Methods Clin Dev       Date:  2019-09-18       Impact factor: 6.698

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.